Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | RHOA | P61586 | 10/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RHOC | P08134 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17773261 | 0.93 | LMNA (0.61) | ALDH1A1RHOAPOLBRAB9ALMNA | |
| SCHEMBL17729029 | 0.90 | ALDH1A1 (0.67) | ALDH1A1RHOAPOLBRAB9ALMNA | |
| SCHEMBL17728989 | 0.83 | ALDH1A1 (0.66) | ALDH1A1RHOAPOLBRAB9ALMNA | |
| SCHEMBL17773260 | 0.82 | RHOA (0.57) | ALDH1A1RHOAPOLBRAB9ALMNA | |
| SCHEMBL17773240 | 0.82 | ALDH1A1 (0.43) | ALDH1A1RHOARAB9ASMN1; SMN2 | |
| SCHEMBL17773268 | 0.80 | RHOA (0.59) | ALDH1A1RHOAPOLBRAB9ALMNA | |
| SCHEMBL29621758 | 0.79 | GHSR (0.48) | ALDH1A1RHOARHOC | |
| SCHEMBL17773225 | 0.79 | RHOA (0.62) | ALDH1A1RHOAPOLBRAB9A | |
| SCHEMBL17773265 | 0.77 | ALDH1A1 (0.61) | ALDH1A1RHOAPOLBRAB9ALMNA | |
| SCHEMBL17773223 | 0.77 | RHOA (0.62) | ALDH1A1RHOARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145251-A1 | INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | SREBF1, SREBF2, BPTF | ALDH1A1 2475/4885RHOA 229/4885POLB 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.